Abbott Laboratories (NYSE:ABT) insider Brian J. Blaser sold 23,866 shares of Abbott Laboratories stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $55.55, for a total value of $1,325,756.30. Following the transaction, the insider now directly owns 146,387 shares of the company’s stock, valued at approximately $8,131,797.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Abbott Laboratories (ABT) traded down $0.13 during mid-day trading on Wednesday, reaching $54.66. The company had a trading volume of 7,828,595 shares, compared to its average volume of 6,609,666. The stock has a market capitalization of $95,228.27, a PE ratio of 22.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06. Abbott Laboratories has a 12 month low of $37.42 and a 12 month high of $56.69. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.59 earnings per share. equities research analysts predict that Abbott Laboratories will post 2.49 earnings per share for the current year.
A number of research firms recently weighed in on ABT. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. J P Morgan Chase & Co began coverage on Abbott Laboratories in a research report on Friday, October 6th. They issued a “neutral” rating and a $60.00 target price for the company. Royal Bank Of Canada restated a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Cowen set a $68.00 price objective on Abbott Laboratories and gave the company a “buy” rating in a research report on Thursday, October 19th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $53.00 price objective on shares of Abbott Laboratories in a research report on Friday, September 1st. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average target price of $56.81.
A number of institutional investors have recently added to or reduced their stakes in the business. Heritage Trust Co lifted its holdings in shares of Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after purchasing an additional 200 shares in the last quarter. Tributary Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter valued at $106,000. Winfield Associates Inc. lifted its holdings in shares of Abbott Laboratories by 3.9% during the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after purchasing an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. lifted its holdings in shares of Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after purchasing an additional 370 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its holdings in shares of Abbott Laboratories by 349.0% during the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after purchasing an additional 2,094 shares in the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://stocknewstimes.com/2017/12/06/abbott-laboratories-abt-insider-brian-j-blaser-sells-23866-shares.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.